ANTIGON SA

Qui sommes nous ?

Based on 2 patents from ULB, ANTIGON is currently developing, with a consortium of regional and international partners/subcontractors, a first disruptive ABO POCT device aiming to improve drastically transfusion safety at bedside.

Informations

Biopark, Rue Auguste Picard 48
6041 Gosselies

Site Web : antigon.eu

Contact

odile jaume - Chief Strategy Officer